Trade Alert: The Independent Non-Executive Director Of Tissue Regenix Group plc (LON:TRX), Brian Phillips, Has Just Spent UK£55k Buying 142% More Shares

By
Simply Wall St
Published
September 27, 2021
AIM:TRX
Source: Shutterstock

Whilst it may not be a huge deal, we thought it was good to see that the Tissue Regenix Group plc (LON:TRX) Independent Non-Executive Director, Brian Phillips, recently bought UK£55k worth of stock, for UK£0.0061 per share. Even though that isn't a massive buy, it did increase their holding by 142%, which is arguably a good sign.

Check out our latest analysis for Tissue Regenix Group

Tissue Regenix Group Insider Transactions Over The Last Year

In fact, the recent purchase by Brian Phillips was the biggest purchase of Tissue Regenix Group shares made by an insider individual in the last twelve months, according to our records. So it's clear an insider wanted to buy, at around the current price, which is UK£0.0062. That means they have been optimistic about the company in the past, though they may have changed their mind. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. The good news for Tissue Regenix Group share holders is that insiders were buying at near the current price.

Tissue Regenix Group insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
AIM:TRX Insider Trading Volume September 27th 2021

Tissue Regenix Group is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Does Tissue Regenix Group Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data indicates that Tissue Regenix Group insiders own about UK£4.8m worth of shares (which is 11% of the company). Whilst better than nothing, we're not overly impressed by these holdings.

So What Does This Data Suggest About Tissue Regenix Group Insiders?

It's certainly positive to see the recent insider purchase. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Tissue Regenix Group insiders are expecting a bright future. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. While conducting our analysis, we found that Tissue Regenix Group has 2 warning signs and it would be unwise to ignore them.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

When trading Tissue Regenix Group or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.Promoted

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.